RYAH Group Inc. (CSE: RYAH) Releases Medical Cannabis Report on Cancer and Adverse Cancer Treatment Effects

 

• RYAH recently released report highlighting medical cannabis treatment for cancer and adverse effects of cancer treatment
• Data from 80,000 sessions logged between January 1, 2018 and November 15, 2021 tracked conditions including anxiety, cachexia, fatigue, pain, nausea, and stress
• 62% of patients reported a moderate experience using cannabis to treat cancer-related conditions
• RYAH supports cancer research and treatment with IoT product ecosystem comprised of volume-control devices, medicine-carrying components, mobile applications

RYAH Group (CSE: RYAH), the leader in volume-control technology for plant-based medicine, recently released a medical cannabis report on cancer and the adverse effects of cancer treatment (https://ibn.fm/Es52b). Data from 80,000 sessions logged between January 1, 2018, and November 15, 2021, tracked conditions that occur with a cancer diagnosis or are associated with cancer treatments. Conditions highlighted in the report included anxiety, cachexia, fatigue, pain, nausea, and stress. 

According to the report, patients preferred Sativa and Sativa-dominant strains for anxiety and stress, with an equal split of Indica-dominant and Sativa-dominant strains for pain. Sixty-two percent of patients reported a moderate experience with cannabis, suggesting that respondents found relief from one or more of these symptoms. While there seem to be rising rates of cancer patients exploring cannabis use, according to the report, the evidence collected to date does not currently support this application due in part to a lack of robust, randomized control trials.

RYAH’s technology supports cannabis research for the treatment of cancer with innovative technology that collects, analyzes, and leverages objective data on therapeutic plant usage. By using the company’s smart devices and integrated AI-powered platform, patients and doctors can stay on top of prescription treatments in a safe, secure, and seamless way. 

RYAH’s current portfolio integrates IoT devices, medicine-carrying components, and mobile applications to create an ecosystem that enables practitioners and patients to administer treatments, control volume, collect data, and produce analytics that can power insights for research purposes. Current products in the pipeline include a Smart Dry-Herb Dose-Measuring Inhaler in the commercial stage, a Smart Transdermal Patch in the production stage, and a Smart Liquid Dispensing Pen in the prototype stage.

The RYAH Smart Inhaler is a medically certified device under ISO 13485 standards. The device provides consistent and predictable results by allowing users to control and track medicine administration. When connected to the RYAH Health App, practitioners can monitor statistics, temperature presets, and volume amounts to customize treatment and improve results. RYAH’s alternative treatment protocol – the RYAH Smart Transdermal Patch – features a lightweight, reusable, mobile-controlled patch that can be applied for site-specific therapies and controlled with a mobile application to allow scheduled and on-demand “boosting” if required. 

RYAH’s Smart Pen will leverage a customized multi-component treatment approach with an app-controlled liquid dispenser that allows multiple medicine components to be combined to produce an “entourage effect.” Using cartridges that contain CBD, THC, other cannabis isolates, and vitamins, the Smart Pen controls volume with a built-in mechanism that draws data from a mobile application. 

RYAH’s doctor collaboration platform, RYAH MD, allows doctors to create digital recommendations for patients and track patient usage for all RYAH IoT devices. RYAH MD will allow doctors to have more oversight on patient use of cannabis products, enabling them to develop highly customized regimens.

RYAH holds a unique position at the intersection of the $100.3 billion medical plant market (https://ibn.fm/GVHHK) and IoT and Data Intelligence sectors. As the leading data technology company in plant-based medicine, RYAH is committed to helping researchers produce valuable insights that transform patient care with the power of big data and artificial intelligence. 

For more information, visit the company’s website at www.RYAHGroup.com.

NOTE TO INVESTORS: The latest news and updates relating to RYAH are available in the company’s newsroom at https://ibn.fm/RYAH

About QualityStocks

QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.

QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com

Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php